Increased neutrophil apoptosis in chronic fatigue syndrome

G Kennedy, V Spence, C Underwood, J J F Belch

**Background/Aims:** Many patients with chronic fatigue syndrome (CFS) have symptoms that are consistent with an underlying viral or toxic illness. Because increased neutrophil apoptosis occurs in patients with infection, this study examined whether this phenomenon also occurs in patients with CFS.

**Methods:** Apoptosis was assessed in patients with CFS in conjunction with concentrations of the anti-inflammatory cytokine, transforming growth factor β1 (TGFβ1).

**Results:** The 47 patients with CFS had higher numbers of apoptotic neutrophils, lower numbers of viable neutrophils, increased annexin V binding, and increased expression of the death receptor, tumour necrosis factor receptor-I, on their neutrophils than did the 34 healthy controls. Patients with CFS also had raised concentrations of active TGFβ1 (p < 0.005).

**Conclusions:** These findings provide new evidence that patients with CFS have an underlying detectable abnormality in their immune cells.

Chronic fatigue syndrome (CFS) is a debilitating condition that has no known aetiology or pathophysiology. In a search for a diagnostic test, recent gene profiling research has confirmed the heterogeneous nature of CFS, supporting the need for continued clinical screening based on the exclusion of other diseases in association with the presence of specific symptoms. Some of these symptoms are suggestive of an underlying viral or toxic illness associated with persistent infection and immune activation. There have been various reports of immunological disturbances and viral infections in the illness.

“Minor alterations to neutrophil function can have profound immunological consequences, with amplification of the inflammatory response and the production of cytokines”

Neutrophils make up 50–60% of the total circulating white blood cells. They are short lived reactive cells that are fundamental to the functioning of an intact immune system. Minor alterations to neutrophil function can have profound immunological consequences, with amplification of the inflammatory response and the production of cytokines. As part of the resolution of inflammation, accumulated neutrophils are removed by apoptosis, a process where unwanted or damaged cells are eliminated without releasing their toxic contents and enhancing the inflammatory response. It is also a process associated with the release of anti-inflammatory mediators; most specifically, the production of transforming growth factor-β1 (TGFβ1), which has been implicated in the pathogenesis of CFS.

Although increased neutrophil apoptosis is present in patients with infection, there have been no reports of neutrophil function in patients with CFS. The aim of our study was to compare elements of neutrophil apoptosis and TGFβ1 in patients with CFS with a control group of age and sex matched healthy subjects.

**METHODS**

Forty seven patients selected by clinical examination to fulfil the Centre for Disease Control classification of CFS and 34 sex and aged matched healthy subjects volunteered for the study (table 1). All subjects gave written informed consent and the local medical ethics committee approved the study.

Neutrophils were separated from whole blood after sedimentation with dextran and histopaque density gradient centrifugation. The neutrophils were immediately incubated with annexin V and/or propidium iodide (PI), as described by literature enclosed in the TACS annexin V FITC kit (R&D Systems, Abingdon, Oxfordshire, UK). Exposure of phosphatidylserine on the outer leaflet of the cytoplasmic membrane is characteristic of early apoptosis and is associated with preferential binding of annexin V. Cells with an intact plasma membrane exclude PI and this property is maintained in those cells that are in the early stages of apoptosis. In contrast, necrotic cells have lost their membrane integrity and stain with PI. Neutrophils that were positive for annexin V only were termed early apoptotic, neutrophils that were positive for both annexin V and PI were termed late apoptotic and/or necrotic, and neutrophils that were positive for neither were classified as viable cells. Leucocyte tumour necrosis factor receptor I (TNFRI) surface expression was measured on a second whole blood sample using a fluorescent labelled antibody, as described in the product insert (R&D Systems; FAB225F). The remaining blood sample was used to prepare platelet poor plasma (PPP) and activated TGFβ1 were measured in the PPP by enzyme linked immunosorbent assay (R&D Systems). TGFβ1 is present in platelet granules and is released after platelet activation; therefore, PPP values are representative of circulating concentrations.

All blood samples were taken at the same time of day and all tests performed by the same person. The data were normally distributed and an unpaired t test was used to compare the mean values of all the parameters between the two subject groups.

**RESULTS**

Staining for annexin V and PI showed that patients with CFS had significantly more apoptotic (p = 0.002) and significantly fewer viable neutrophils (p = 0.002) than did healthy controls. There was a trend for patients with CFS to have later apoptotic/necrotic neutrophils (p = 0.075). The patients’ neutrophils also showed increased annexin V binding (p = 0.001; 37.4% compared with 22.8% in the control group). Mean annexin V expression in the control group (22.8%) was similar to that reported by others.

**Abbreviations:** CFS, chronic fatigue syndrome; PI, propidium iodide; PPP, platelet poor plasma; TGFβ1, transforming growth factor β1; TNFRI, tumour necrosis factor receptor I
The relatively large range is a result of the methodological differences between various laboratories necessitating good laboratory practice to make certain that all samples are treated identically. The expression of neutrophil TNFRI was also significantly higher in the patient group (p = 0.004).

There were significantly greater amounts of activated TGFβ1 in the PPP of patients with CFS than in the healthy matched control subjects (p = 0.005).

**DISCUSSION**

We have shown that there are a greater proportion of apoptotic cells among neutrophils isolated from patients with CFS and that these cells are significantly less viable when compared with those from healthy subjects. The same neutrophils expressed more TNFRI death receptor molecules and had increased binding of annexin V, indicative of phosphatidylserine exposure.

Apoptosis is triggered by signals initiated both by external stimuli and internal sensors. The death receptor mediated pathway, also known as the extrinsic pathway, starts with the binding of TNF family ligands to the death receptor TNFRI. This results in the recruitment of an adaptor protein, TNFR associated death domain, which in turn recruits another adaptor molecule, the Fas associated death domain. The Fas associated death domain then recruits procaspase 8 or procaspase 10 to form a death inducing signal complex. During the formation of the death inducing signal complex, procaspase forms are cleaved and converted, with the release of activated caspase 8 or caspase 10, which directly convert other procaspases to their active forms, thereby initiating apoptosis. However, there is crosstalk between the extrinsic and intrinsic (mitochondrial dependent) pathways, and cleavage of the proapoptotic protein, Bid, by caspase 8 can occur. This cleavage can result in the release of cytochrome C and the triggering of further apoptotic mechanisms. In our study, we have shown that the neutrophils of patients with CFS have increased expression of TNFRI and we can only surmise that the accelerated apoptosis of these cells is a consequence of extrinsic factors affecting apoptotic pathways.

In addition, we found that the concentrations of activated TGFβ1 were significantly raised in the PPP of patients with CFS. An increase in activated TGFβ1 in conjunction with neutrophil apoptosis is an important process in the down-regulation of cytokines and eicosanoid production during the chronic inflammatory process. TGFβ1 is also crucial in the apoptotic process because it curbs leucocyte adhesion and transmigration, and this impairment of the transmigratory process of neutrophils may independently promote apoptosis. Neutrophils that transmigrate across the endothelium lose TNF receptors and this loss of receptor density is necessary for the survival of the neutrophil. The fact that neutrophils from patients with CFS have increased surface expression of TNFRI is a further indication that such cells are more susceptible to apoptosis.

The neutrophils of patients with CFS have an increased rate of apoptosis and this may impact on the innate immune system of these patients, given that neutrophils are the major effector cells of this system. The control of apoptosis is complex, and the increased rate of apoptosis in patients with CFS may be a consequence of several factors. Accelerated apoptosis is indicative of a persistent or reactivating viral infection or a toxic state, reprogramming of apoptotic pathways by an infectious or toxic agent, or quicker neutrophil turnover, secondary to an abnormal host response to nosiologic stimuli. With the advent of gene profiling the search is on for causative agents in CFS. The data presented here are consistent with the fact that many patients with CFS have an underlying, detectable abnormality in the behaviour of their immune cells, consistent with an activated inflammatory process.

**Take home messages**

- Patients with chronic fatigue syndrome (CFS) had higher numbers of apoptotic neutrophils, lower numbers of viable neutrophils, increased annexin V binding, and increased expression of the death receptor, tumour necrosis factor receptor I, on their neutrophils than healthy controls.
- Patients with CFS also had raised concentrations of active transforming growth factor β1.
- Thus, patients with CFS appear to have an underlying abnormality in their immune cells.

“The data presented here are consistent with the fact that many patients with chronic fatigue syndrome have an underlying, detectable abnormality in the behaviour of their immune cells, consistent with an activated inflammatory process.”
ACKNOWLEDGEMENTS
The study was funded by the charity ME Research Group for Education and support (MERGE), Perth, UK. Further support was also received from the Sir John Fisher Foundation (educational grant).

Authors’ affiliations
G Kennedy, V Spence, C Underwood, J J F Belch, Vascular Diseases Research Unit, University Department of Medicine, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK

Correspondence to: Dr G Kennedy, Vascular Diseases Research Unit, Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; g.kirk@dundee.ac.uk

Accepted for publication 15 March 2004

REFERENCES